<- Go Home
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$11.7B
Volume
2.2M
Cash and Equivalents
$461.5M
EBITDA
-$695.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$264.9M
Profit Margin
77.25%
52 Week High
$80.53
52 Week Low
$21.92
Dividend
N/A
Price / Book Value
24.14
Price / Earnings
-11.73
Price / Tangible Book Value
36.87
Enterprise Value
$11.4B
Enterprise Value / EBITDA
-17.32
Operating Income
-$703.9M
Return on Equity
890.75%
Return on Assets
-26.05
Cash and Short Term Investments
$1.5B
Debt
$1.2B
Equity
$483.4M
Revenue
$343.0M
Unlevered FCF
-$333.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium